ORLANDO—Lenalidomide maintenance therapy extended times to disease progression among patients whose multiple myeloma had been treated with autologous stem cell transplantation in a phase III study rep
Philip McCarthy
ORLANDO—Lenalidomide maintenance therapy extended times to disease progression among patients whose multiple myeloma had been treated with autologous stem cell transplantation in a phase III study reported at the American Society of Hematology annual meeting (December 3-7, 2010) in Orlando. Philip McCarthy, Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York, discusses the clinical implications of his group’s findings with eCancer Radio.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/101209PhilipMcCarthyPODCASTLoRes.mp3]
Related Episodes
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.
Juan Du MD PhD, ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma
Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.
María-Victoria Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings
This podcast episode, recorded at ASH 2025, features an interview with María-Victoria Mateos MD PhD, who discusses groundbreaking findings from the Majestec-3 study. The study highlights unprecedented survival benefits with the BCMA/CD3 bispecific antibody teclistamab. In patients with relapsed or refractory multiple myeloma, adding teclistamab to standard second-line therapies significantly improved progression-free and overall survival.